NCT05271799View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

April 22, 2022

Study Completion Date

April 22, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

Gepotidacin

Gepotidacin will be administered

Trial Locations (1)

89113

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY